Sponsor content
41 result(s) found, displaying 1 to 10
- Australian Public Assessment Report (AusPAR)AusPAR: YuflymaAusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.
- Prescription medicine decision summaryYuflymaTGA Decision: Yuflyma (adalimumab) is approved to treat multiple auto-immune conditions.
- ARTGYUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe (358350)Australian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe.
- ARTGYUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe in autoinjector (367771)Australian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe in autoinjector.
- ARTGYUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe with a safety guard (367770)Australian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab (rch) 40 mg/0.4 mL solution for injection pre-filled syringe with a safety guard.
- Prescription medicine registrationYUFLYMA (Celltrion Healthcare Australia Pty Ltd)Active ingredients: adalimumab.
- Australian Public Assessment Report (AusPAR)AusPAR: RegdanvimabAustralian Public Assessment Report for Regdanvimab
- Prescription medicine registrationREGKIRONA (Celltrion Healthcare Australia Pty Ltd)Active ingredients: regdanvimab.
- ARTGREGKIRONA regdanvimab (rch) 960mg/16mL concentrate for solution for infusion (374190)Australian Register of Therapeutic Goods (ARTG) information for REGKIRONA regdanvimab (rch) 960mg/16mL concentrate for solution for infusion.
- Designation or determinationNotice for regdanvimab (Celltrion Healthcare Australia Pty Ltd)Provisional approval